Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer. 2016

Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
Department of Urology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.

The present study aimed to investigate the potential mechanisms used during signal transduction by M3 muscarinic acetylcholine receptor (CHRM3) in prostate cancer. The microarray datasets of GSE3325, including 5 clinically localized primary prostate cancers and 4 benign prostate tissues, were downloaded from the Gene Expression Omnibus database. The differentially-expressed genes (DEGs) in primary prostate cancer tissues compared with benign controls were screened using the Limma package. Gene Ontology and pathway enrichment analyses were performed using the Database for Annotation Visualization and Integrated Discovery. Next, a protein-protein interaction (PPI) network was constructed. Additionally, microRNAs (miRNAs) associated with DEGs were predicted and miRNA-target DEG analysis was performed using a Web-based Gene Set Analysis Toolkit. Finally, the PPI network and the miRNA-target DEG network were integrated using Cytoscape. In total, 224 DEGs were screened in the prostate cancer tissues, including 113 upregulated and 111 downregulated genes. CHRM3 and epidermal growth factor (EGF) were enriched in the regulation of the actin cytoskeleton. EGF and v-myc avian myelocytomatosis viral oncogene homolog (Myc) were enriched in the mitogen-activated protein kinase (MAPK) signaling pathway. EGF with the highest degree of connectivity was the hub node in the PPI network, and miR-34b could interact with Myc directly in the miRNA-target DEG network. EGF and Myc may exhibit significant roles in the progression of prostate cancer via regulation of the actin cytoskeleton and the MAPK signaling pathway. CHRM3 may activate these two pathways in prostate cancer progression. Thus, these two key factors and pathways may be crucial mechanisms during signal transduction by CHRM3 in prostate cancer.

UI MeSH Term Description Entries

Related Publications

Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
October 1993, The EMBO journal,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
September 1994, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
October 1998, Toxicology in vitro : an international journal published in association with BIBRA,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
May 2024, Molecular pharmacology,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
December 2014, International journal of cardiology,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
March 2002, American journal of respiratory cell and molecular biology,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
January 1990, Society of General Physiologists series,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
December 2022, The Journal of investigative dermatology,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
August 2004, Journal of pharmacological sciences,
Liqiang Guo, and Yuqiang Liu, and Zhibo Ding, and Wendong Sun, and Mingzhen Yuan
August 2008, Molecular pharmacology,
Copied contents to your clipboard!